P-glycoprotein limits the brain penetration of nonsedating but not sedating H1-antagonists

Drug Metabolism and Disposition

Volumn 31, Issue 3, 2003, Pages 312-318

  Chen, Cuiping ^a,b   Hanson, Elizabeth ^a   Watson, John W ^a   Lee, Jae S ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CETIRIZINE; DESLORATADINE; DIPHENHYDRAMINE; GLYCOPROTEIN P; HISTAMINE H1 RECEPTOR ANTAGONIST; HYDROXYZINE; LORATADINE; MULTIDRUG RESISTANCE PROTEIN 1; TRIPROLIDINE;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CELL STRAIN; CENTRAL NERVOUS SYSTEM DISEASE; CONTROLLED STUDY; DOG; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG PENETRATION; DRUG TRANSPORT; GENETIC TRANSFECTION; KNOCKOUT GENE; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; WILD TYPE;

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; BRAIN; HISTAMINE H1 ANTAGONISTS; HISTAMINE H1 ANTAGONISTS, NON-SEDATING; HYPNOTICS AND SEDATIVES; MALE; MICE; MICE, KNOCKOUT; P-GLYCOPROTEIN; P-GLYCOPROTEINS;

ANIMALIA; CANIS FAMILIARIS;

EID: 0037372571     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: 10.1124/dmd.31.3.312     Document Type: Article

References (31)

1. Adachi Y, Suzuki H, and Sugiyama Y (2001) Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res (NY) 18:1660-1668.
2. Borst P, Evers R, Kool M, and Wijnholds J (1999) The multidrug resistance protein family. Biochim Biophys Acta 1461:347-357.
3. Chishty M, Reichel A, Siva J, Abbott NJ, and Begley DJ (2001) Affinity for the P-glycoprotein efflux pump at the blood-brain barrier may explain the lack of CNS side-effects of modern antihistamines. J Drug Target 9:223-228.
4. 2.5] enkephalin in mdr1a-gene-deficient mice. J Pharmacol Exp Ther 287:545-552.
5. Clissold SP, Sorken EM, and Goa KL (1989) Loratadine. A preliminary review of its pharmacodynamic properties and therapeutic efficacy. Drugs 37:42-57.
6. Cvetkovic M, Leake B, Fromm MF, Wilkinson GR, and Kim RB (1999) OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos 27:866-871.
7. Dagenais C, Zong J, Ducharme J, and Pollack GM (2001) Effect of mdr1a P-glycoprotein gene disruption, gender and substrate concentration on brain uptake of selected compounds. Pharm Res (NY) 18:957-963.
8. Elmquist WF and Miller DW (2001) The use of transgenic mice in pharmacokinetic and pharmacodynamic studies. J Pharm Sci 90:422-435.
9. Gibaldi M and Perrier D (1982) Pharmacokinetics, Marcel Dekker, New York.
10. Hait WN, Gesmonde JF, Murren JR, Yang JM, Chen HX, and Reiss M (1993) Terfenadine (Seldane): a new drug for restoring sensitivity to multidrug resistant cancer cells. Biochem Pharmacol 45:401-406.
11. Kay GG and Harris AG (1999) Loratadine: a non-sedating antihistamine. Review of its effects on cognition, psychomotor performance, mood and sedation. Clin Exp Allergy 29 (Suppl 3):147-150.
12. Kim RB, Wandel C, Leake B, Cvetkovic M, Fromm MF, Dempsey PJ, Roden MM, Belas F, Chaudhary AK, Roden DM, et al. (1999) Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm Res (NY) 16:408-414.
13. Kusuhara H, Suzuki H, Terasaki T, Kakee A, Lemaire M, and Sugiyama Y (1997) P-Glycoprotein mediates the efflux of quinidine across the blood-brain barrier. J Pharmacol Exp Ther 283:574-580.
14. 6-fold increased cell sensitivity to verocytotoxin: role of P-glycoprotein in glycolipid synthesis. J Biol Chem 275:6246-6251.
15. Paakkari I (2002) Cardiotoxicity of new antihistamines and cisapride. Toxicol Lett 127:279-284.
16. Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, and Serabjit-Singh CS (2001) Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther 299:620-628.
17. Radwanski E, Hilbert J, Symchowicz S, and Zampaglione N (1987) Loratadine, multiple-dose pharmacokinetics. J Clin Pharmacokinet 27:530-533.
18. Raeissi SD, Hidalgo IJ, Segura-Aguilar J, and Artursson P (1999) Interplay between CYP3A-mediated metabolism and polarized efflux of terfenadine and its metabolites in intestinal epithelial Caco-2 (TC7) cell monolayers. Pharm Res (NY) 16:625-632.
19. Scarborough GA (1995) Drug-stimulated ATPase activity of the human P-glycoprotein. J Bioengerg Biomembr 27:37-41.
20. Schinkel AH (1998) Pharmacological insights from P-glycoprotein knockout mice. Int J Clin Pharmacol Ther 36:9-13.
21. Schinkel AH, Mayer U, Wagenaar E, Mol CA, van Deemter L, Smit JJ, van der Valk MA, Voordouw AC, Spits H, van Tellingen O, et al. (1997) Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proc Natl Acad Sci USA 94:4028-4033.
22. Schinkel AH, Smit JJ, van Tellingen O, Beijnen JH, Wagenaar E, van Deemter L, Mol CA, van der Valk MA, Robanus-Maandag EC, te Riele HPJ, et al. (1994) Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77:491-502.
23. Shapiro AB, Fox K, Lam P, and Ling V (1999) Stimulation of P-glycoprotein-mediated drug transport by prazosin. Eur J Biochem 259:841-850.
24. Simons EFR (1999) H1-receptor antagonists: safety issues. Ann Allergy Asthma Immunol 83:481-488.
25. Soldner A, Christians U, Susanto M, Wacher VJ, Silverman JA, and Benet LZ (1999) Grapefruit juice activates P-glycoprotein-mediated drug transport. Pharm Res (NY) 16:478-485.
26. Timmerman H (1999) Why are non-sedating antihistamines non-sedating? Clin Exp Allergy 29 (Suppl 3):13-18.
27. Timmerman H (2000) Factors involved in the absence of sedative effects by the second-generation antihistamines. Allergy 55 (Suppl 60):5-10.
28. Wang E, Casciano CN, Clement RP, and Johnson WW (2001) Evaluation of the interaction of loratadine and desloratadine with P-glycoprotein. Drug Metab Dispos 29:1080-1083.
29. Yanai K, Okamura N, Tagawa M, Itoh M, and Watanabe T (1999) New findings in pharmacological effects induced by antihistamines: from PET studies to knock-out mice. Clinic Exp Allergy 29:29-36.
30. Yokogawa K, Takahashi M, Tamai I, Konishi H, Nomura M, Moritani S, Miyamoto K, and Tsuji A (1999) P-glycoprotein-dependent disposition kinetics of tacrolimus: studies in mdr1a knockout mice. Pharm Res (NY) 16:1213-1218.
31. Yumibe N, Huie K, Chen KJ, Snow M, Clement RP, and Cayen MN (1996) Identification of human liver cytochrome P450 enzymes that metabolize the nonsedating antihistamine loratadine. Formation of descarboethoxyloratadine by CYP3A4 and CYP2D6. Biochem Pharmacol 51:165-172.